Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Epcoritamab SC + GemOx Leads to High Complete Metabolic Response Rates in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Stem Cell Transplant: Updated Results from Epcore NHL-2

Joshua Brody, Judit Mészáros Joergensen, David Belada, Regis T. Costello, Marek Trněný, Umberto Vitolo, David Lewis, Yasmin H. Karimi, Anna Maria Sureda Balari, Marc André, Björn E. Wahlin, Pieternella Lugtenburg, Faith Galderisi, Aqeel Abbas, Yaou Song, Malene Risum, Raul Cordoba

Blood (2023) 142 (Supplement 1): 3092.

https://doi.org/10.1182/blood-2023-180246

Published: 2023

Journal Articles

Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Receiving Ibrutinib on the Phase 3 ASPEN Study ≥1 Year After Transitioning to Zanubrutinib

Ramon Garcia-Sanz, Roger Owen, Wojciech Jurczak, Meletios A. Dimopoulos, Helen McCarthy, Gavin Cull, Stephen Opat, Jorge J. Castillo, Marie José Kersten, Björn E. Wahlin, Sebastian Grosicki, Radha Prathikanti, Tian Tian, Heather Allewelt, Aileen Cleary Cohen, Constantine S. Tam

Blood (2023) 142 (Supplement 1): 3043.

https://doi.org/10.1182/blood-2023-174294

Published: 2023

Journal Articles

Long-Term Efficacy of a 6-Month Regimen of Rituximab and Lenalidomide in Follicular Lymphoma Patients in Need of First Therapy: Updated Analysis of the SAKK 35/10 Randomized Trial

Blood (2023) 142 (Supplement 1): 295.

https://doi.org/10.1182/blood-2023-173957

Published: 2023

Journal Articles

FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma

Blood (2022) 140 (Supplement 1): 2292–2295.

https://doi.org/10.1182/blood-2022-157194

Published: 2022

Journal Articles

Rituximab Infusion in 30 Minutes’ Is Safe and Improves the Flow of Outpatients with Lymphoma Treatment (SPEEDR)

Björn E Wahlin, Therese Rådman, Maria Ljungqvist, Kristina Sonnevi

Blood (2022) 140 (Supplement 1): 10790.

https://doi.org/10.1182/blood-2022-160028

Published: 2022

Journal Articles

Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R 2 ) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

Blood (2022) 140 (Supplement 1): 1471–1473.

https://doi.org/10.1182/blood-2022-158232

Published: 2022

Journal Articles

Treatment Sequencing and Survival in Follicular Lymphoma: A National Population-Based Study

Tove Wästerlid, Anna Warnqvist, Caroline E. Weibull, Björn E Wahlin, P-O Andersson, Gunilla Enblad, Eva Kimby, Karin Ekstroem Smedby

Blood (2022) 140 (Supplement 1): 3620–3621.

https://doi.org/10.1182/blood-2022-164550

Published: 2022

Journal Articles

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

Ryan C. Lynch, MD, Shankara Paneesha, MD, Abraham Avigdor, MD, Matthew S McKinney, Björn E Wahlin, MD PhD, John S Hrom, David Belada, MD PhD, Miguel Canales, David Cunningham, MD FRCP, FMedSci, Liliana Devizzi, Nicholas Morley, Fred Zheng, MD, Douglas J DeMarini, PhD, Wei Jiang, PhD, Marek Trněný, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-134869

Published: 2020

Journal Articles

Outcome By Primary Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A Large, Population-Based Study in Sweden

Caroline Weibull, Björn E Wahlin, MD PhD, Sandra Lockmer, Gunilla Enblad, Per-Ola Andersson, MD PhD, Eva Kimby, MD PhD, Karin E. Smedby, MD PhD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-140228

Published: 2020

Journal Articles

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Blood (2020) 136 (18): 2038–2050.

https://doi.org/10.1182/blood.2020006844

Published: 2020

Includes: Supplemental data

Journal Articles

Incidence of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Including CNS Relapse in a Population-Based Cohort of 4205 Patients in Sweden

Sara Harrysson, MD, Sandra Eloranta, Sara Ekberg, Gunilla Enblad, Mats Jerkeman, MD Professor, Sverker Hasselblom, Björn E Wahlin, MD PhD, Per-Ola Andersson, MD PhD, Karin E. Smedby, MD PhD

Blood (2019) 134 (Supplement_1): 399.

https://doi.org/10.1182/blood-2019-122014

Published: 2019

Journal Articles

Outcome of Patients with Hodgkin Lymphoma Treated with Brentuximab Vedotin for Relapse after Autologous Stem Cell Transplant: A Retrospective Analysis of the LWP-EBMT

Blood (2019) 134 (Supplement_1): 4018.

https://doi.org/10.1182/blood-2019-131410

Published: 2019

Journal Articles

A Clinical Trial of Cannabis As Targeted Therapy for Indolent Leukemic Lymphoma

Christopher M Melén, MD, Magali Merrien, MSc, Agata Wasik, MSc, PhD, Kristina Sonnevi, MD PhD, Henna-Riikka Junlén, MD, Birger Christersson, MD PhD, Birgitta Sander, MD PhD Prof., Björn E Wahlin, MD PhD

Blood (2019) 134 (Supplement_1): 5487.

https://doi.org/10.1182/blood-2019-126693

Published: 2019

Journal Articles

System-Level Disease-Driven Immune Signatures in Patients with Diffuse Large B-Cell Lymphoma Associated with Poor Survival

Astrid Tschan-Plessl, MD, Eivind Heggernes Ask, Thea Johanne Gjerdingen, Michelle Saetersmoen, Hanna Julie Hoel, Merete Thune Wiiger, Msc, Johanna Olweus, Björn E Wahlin, MD PhD, Amir Horowitz, PhD, Todd A Fehniger, MD PhD, Harald Holte, MD PhD, Arne Kolstad, MD PhD, Karl-Johan Malmberg, MD PhD

Blood (2019) 134 (Supplement_1): 2897.

https://doi.org/10.1182/blood-2019-131359

Published: 2019

Journal Articles

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

Blood (2019) 134 (4): 353–362.

https://doi.org/10.1182/blood-2018-10-879643

Published: 2019

Includes: Supplemental data

Journal Articles

Cannabinoid Receptors and CXCR4 Cross-Talk in Lymphoma Cells

Magali Merrien, MSc, Agata Magdalena Wasik, PhD MSc, Christopher Melén, MD, Kristina Sonnevi, MD PhD, Birger Christensson, MD PhD, Björn E Wahlin, Birgitta Sander, MD PhD

Blood (2018) 132 (Supplement 1): 4121.

https://doi.org/10.1182/blood-2018-99-112096

Published: 2018

Journal Articles

M7-FLIPI Not Valid in Follicular Lymphoma Patients with First-Line Rituximab Chemo-Free Therapy

Sandra Lockmer, MD, Weicheng Ren, PhD, Bjorn Ostenstad, MD PhD, Marianne Brodtkorb, MD PhD, Björn E Wahlin, Qiang Pan-Hammarstrom, MD PhD, Eva Kimby, MD PhD

Blood (2018) 132 (Supplement 1): 4154.

https://doi.org/10.1182/blood-2018-99-117949

Published: 2018

Journal Articles

The PRIMA-Prognostic Index (PI) Is Valid in Follicular Lymphoma (FL) Patients with Rituximab Chemo-Free First-Line Treatment

Eva Kimby, MD PhD, Sandra Lockmer, MD, Harald Holte, MD PhD, Björn E Wahlin, Hans Hagberg, MD, Peter De Nully Brown, Björn Östenstad, MD

Blood (2018) 132 (Supplement 1): 4150.

https://doi.org/10.1182/blood-2018-99-114866

Published: 2018

Journal Articles

Incidence and Outcome of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Cohort of 3165 Patients in Sweden

Sara Harrysson, MD, Sandra Eloranta, Sara Ekberg, Gunilla Enblad, Mats Jerkeman, Sverker Hasselblom, Björn E Wahlin, Per-Ola Andersson, Karin E Smedby

Blood (2018) 132 (Supplement 1): 2975.

https://doi.org/10.1182/blood-2018-99-110672

Published: 2018

Journal Articles

Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10

Blood (2016) 128 (22): 1099.

https://doi.org/10.1182/blood.V128.22.1099.1099

Published: 2016

NARROW

Epcoritamab SC + GemOx Leads to High Complete Metabolic Response Rates in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Stem Cell Transplant: Updated Results from Epcore NHL-2

Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Receiving Ibrutinib on the Phase 3 ASPEN Study ≥1 Year After Transitioning to Zanubrutinib

Long-Term Efficacy of a 6-Month Regimen of Rituximab and Lenalidomide in Follicular Lymphoma Patients in Need of First Therapy: Updated Analysis of the SAKK 35/10 Randomized Trial

FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma

Rituximab Infusion in 30 Minutes’ Is Safe and Improves the Flow of Outpatients with Lymphoma Treatment (SPEEDR)

Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R 2 ) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

Treatment Sequencing and Survival in Follicular Lymphoma: A National Population-Based Study

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

Outcome By Primary Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A Large, Population-Based Study in Sweden

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Incidence of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Including CNS Relapse in a Population-Based Cohort of 4205 Patients in Sweden

Outcome of Patients with Hodgkin Lymphoma Treated with Brentuximab Vedotin for Relapse after Autologous Stem Cell Transplant: A Retrospective Analysis of the LWP-EBMT

A Clinical Trial of Cannabis As Targeted Therapy for Indolent Leukemic Lymphoma

System-Level Disease-Driven Immune Signatures in Patients with Diffuse Large B-Cell Lymphoma Associated with Poor Survival

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

Cannabinoid Receptors and CXCR4 Cross-Talk in Lymphoma Cells

M7-FLIPI Not Valid in Follicular Lymphoma Patients with First-Line Rituximab Chemo-Free Therapy

The PRIMA-Prognostic Index (PI) Is Valid in Follicular Lymphoma (FL) Patients with Rituximab Chemo-Free First-Line Treatment

Incidence and Outcome of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Cohort of 3165 Patients in Sweden

Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only